Antibody and T cell responses of patients with adenocarcinoma immunized with mannan-MUC1 fusion protein

Journal of Clinical Investigation

Volumn 100, Issue 11, 1997, Pages 2783-2792

  Karanikas, Vaios ^a   Hwang, Le Ann ^a   Pearson, Julian ^a   Ong, Chin Swee ^a   Apostolopoulos, Vasso ^a   Vaughan, Hilary ^a   Xing, Pei Xiang ^a   Jamieson, Gary ^a   Pietersz, Geoffrey ^a   Tait, Brian ^b   Broadbent, Russell ^c   Thynne, Grenville ^c   McKenzie, Ian F C ^a  

^a AUSTIN RESEARCH INSTITUTE   (Australia)

^b ROYAL MELBOURNE HOSPITAL   (Australia)

^c Allamanda Medical Centre   (Australia)

Author keywords

Cancer; Epitopes; Immunotherapy; Muc1; Phase I trial; Vaccine

Indexed keywords

HYBRID PROTEIN; IMMUNOGLOBULIN G1; MANNAN; MUCIN;

ADENOCARCINOMA; ADULT; AGED; ANTIBODY RESPONSE; ARTICLE; BREAST ADENOCARCINOMA; CLINICAL ARTICLE; CLINICAL TRIAL; COLON ADENOCARCINOMA; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DOSE RESPONSE; FEMALE; HUMAN; HUMAN CELL; IMMUNIZATION; LYMPHOCYTE PROLIFERATION; MALE; PRIORITY JOURNAL; RECTUM CARCINOMA; STOMACH ADENOCARCINOMA; SUBCUTANEOUS DRUG ADMINISTRATION; T LYMPHOCYTE; VARIABLE NUMBER OF TANDEM REPEAT;

EID: 0031457133     PISSN: 00219738     EISSN: None     Source Type: Journal    
DOI: 10.1172/JCI119825     Document Type: Article

References (59)

1. Taylor-Papadimitriou, J., and S.J. Gendler. 1988. Molecular aspects of Mucins. Cancer Rev. 11:11-24.
2. Hilkens, J., S.V. Lightenberg, H.L. Vos, and S.V. Litvinov. 1992. Cell membrane associated mucins and their adhesion modulating property. TIBS (Trends Biochem. Sci.). 17:359-363.
3. Apostolopoulos, V., and I.F.C. McKenzie. 1994. Cellular mucins: targets for immunotherapy. Crit. Rev. Immunol. 14:293-309.
4. Apostolopoulos, V., G.A. Pietersz, and I.F.C. McKenzie. 1996. Cell-mediated immune response to MUC1 fusion protein coupled to mannan. Vaccine. 14:930-938.
5. Gendler, S.J., J.M. Burchell, T. Duhig, D. Lamport, R. White, M. Parker, and J. Taylor-Papadimitriou. 1987. Cloning of partial cDNA coding differentiation and tumor associated mucin glycoproteins expressed by human mammary epithelium. Proc. Natl. Acad. Sci. USA. 84:6060-6064.
6. Siddiqui, J., M. Abe, D. Hayes, E. Shani, E. Yunis, and D. Kufe. 1988. Isolation and sequencing of cDNA coding for the human DF3 breast carcinoma-associated antigen. Proc. Natl. Acad. Sci. USA. 85:2320-2323.
7. Wreshner, D.H., M. Hareuveni, I. Tsarfaty, N. Smorodinsky, J. Horev, J. Zaretsky, P. Kotkes, M. Weiss, R. Lathe, A. Dion, and I. Keybar. 1990. Human epithelial tumour antigen cDNA sequences-differential splicing may generate multiple protein forms. Eur. J. Biochem. 189:463-474.
8. Itzkowitz, S.H., M. Yuan, C.K. Montgomery, T. Kjeldsen, H.K. Takahashi, W.L. Bigbee, and Y.S. Kim. 1989. Expression of Tn, sialosyl-Tn and T antigens in human colon cancer. Cancer Res. 49:197-204.
9. Xing, P-X., J. Prenzoska, and I.F.C. McKenzie. 1992. Epitope mapping of anti-breast and anti-ovarian mucin monoclonal antibodies. Mol. Immunol. 29: 641-650.
10. Xing, P.-X., J.J. Tjandra, S.A. Stacker, C.H. Thompson, P.J. McLaughlin, and I.F.C. McKenzie. 1989. Monoclonal antibodies reactive with mucin expressed in breast cancer. Immunol. Cell Biol. 67:183-195.
11. Gendler, S.J., and A.P. Spicer. 1995. Epithelial mucin genes. Annu. Rev. Physiol. 57:607-634.
12. Jerome, K.R., D.L. Barnd, K.M. Bendt, C.M. Boyer, J. Taylor-Papadimitriou, I.F.C. McKenzie, R.C. Bast, and O.J. Finn. 1991. Cytotoxic T-lymphocytes derived from patients with breast adenocarcinoma recognize an epitope present on the protein core of a mucin molecule preferentially expressed by malignant cells. Cancer Res. 51:2908-2916.
13. Barnd, D.L., L.A. Kerr, R.S. Metzgar, and O.J. Finn. 1988. Human tumor-specific cytotoxic T cell lines generated from tumour-draining lymph node infiltrate. Transplant. Proc. 20:339-341.
14. Jerome, K.R., N. Domenech, and O.J. Finn. 1993. Tumour-specific CTL clones from patients with breast and pancreatic adenocarcinomas recognize EBV-immortalized B cells transfected with polymorphic epithelial mucin cDNA. J. Immunol. 151:1654-1662.
15. Ioannides, C.G., B. Fisk, K.R. Jerome, T. Irimura, J.T. Wharton, and O.J. Finn. 1993. CTL from ovarian malignant tumours can recognise polymorphic epithelial mucin core peptides. J. Immunol. 151:3693-3703.
16. Takahashi, T., Y. Makiguchi, Y. Hinoda, H. Kakiuchi, N. Nakagawa, K. Imai, and A. Yachi. 1994. Expression of MUC1 on myeloma cells and induction of HLA-unrestricted CTL against MUC1 from a multiple myeloma patient. J. Immunol. 153:2102-2109.
17. Barnd, D.L., M.S. Lans, R.S. Metzgar, and O.J. Finn. 1989. Specific MHC-unrestricted recognition of tumour-associated mucins by human CTL. Proc. Natl. Acad. Sci. USA. 86:7159-7163.
18. Apostolopoulos , V., P.-X. Xing, and I.F.C. McKenzie. 1994. Murine immune response to cells transfected with human MUC1: Immunisation with cellular and synthetic antigens. Cancer Res. 54:5186-5193.
19. Apostolopoulos, V., G.A. Pietersz, B.E. Loveland, M.S. Sandrin, and I.F.C. McKenzie. 1995. Oxidative/reductive conjugation of mannan to antigen selects for T1 or T2 immune responses. Proc. Natl. Acad. Sci. USA. 92:10128-10132.
20. Apostolopoulos, V., B.E. Loveland, G.A. Pietersz, and I.F.C. McKenzie. 1995. CTL in mice immunised with human mucin 1 are MHC-restricted. J. Immunol. 155:5089-5094.
21. Apostolopoulos, V., P.-X. Xing, J.A. Trapani, and I.F.C. McKenzie. 1993. Production of anti-breast cancer monoclonal antibodies using a glutathione-S-transferasc-MUC1 bacterial fusion protein. Br. J. Cancer. 67:713-720.
22. Hodges, R.S., and R.B. Merrifield. 1975. Monitoring of solid phase peptide synthesis by an automated spectrophotometric picrate method. Anal. Biochem. 65:241-272.
23. Kent, S.B.H., and L.E. Hood. 1984. A novel approach to automated peptide synthesis based on new insights into solid phase chemistry. In Peptide Chemistry. A.N. Izumiya, editor. Protein Research Foundation, Osaka, Japan. 217-222.
24. Vaughan, H.A., K.R. Oldenburg, M.A. Gallop, J.D. Atkin, I.F.C. McKenzie, and M.S. Sandrin. 1996. Recognition of an octapeptide sequence by multiple Gal (a1,3)gal-binding proteins. Xenotransplantation. 3:18-23.
25. Sandrin, M.S., H.A. Vaughan, M.A. Gallop, P.-X. Xing, and I.F.C. McKenzie. 1997. Natural human anti-Gal (α1,3)Gal antibodies react with human mucin peptides. Glycoconj. J. 14:97-105.
26. MacLean, G.D., M.D. Bowen-Yacyshyn, J. Samuel, J. Meikle, G. Stuart, J. Nation, S. Poppena, M. Jerry, R. Koganty, T. Wong, and B.M. Longenecker. 1992. Active immunisation of human ovarian cancer patients against a common carcinoma (TF) determinant using a synthetic carbohydrate antigen. J. Immunother. 11:292-300.
27. Geyson, H.M., S.J. Rodda, T.J. Mason, G. Tribbick, and P.G. Schoofs. 1987. Strategies for epitope analysis using peptide synthesis. J. Immunol. Methods. 102:259-274.
28. Karlsson R., A. Michaelsson, and L. Mattsson. 1991. Kinetic analysis of monoclonal antibody-antigen interactions with a new biosensor based analytical system. J. Immunol. Methods. 145:229-240.
29. Fisk, B., C.G. Ioannides, S. Aggarwal, J.T. Wharton, C.A. O'Brian, N. Restifo, and B.S. Glisson. 1994. Enhanced expression of HLA-A,B,C and inducibility of TAP-1, TAP-2, and HLA-A,B,C, by interferon-gamma in a multidrug-resistant small cell lung cancer line. Lymphokine Cytokine Res. 13:125-131.
30. Kotera, Y., J.D. Fontenot, G. Pecher, R.S. Metzga, and O.J. Finn. 1994. Humoral immunity against a tandem repeat epitope of human mucin MUC-1 in sera from breast, pancreatic, and colon cancer patients. Cancer Res. 54:2856-2860.
31. Apostolopoulos, V., I.F.C. McKenzie, and G.A. Pietersz. 1996. Breast cancer immunotherapy: current status and future prospects. Immunol. Cell Biol. 74:457-464.
32. Xing, P.-X., V. Apostolopoulos, M. Michaels, J. Prenzoska, J. Bishop, and I.F.C. McKenzie. 1995. Phase I study of synthetic MUCI peptides in cancer. Int. J. Oncol. 6:1283-1289.
33. Longenecker, B.M., M.A. Reddish, R.R. Koganty, and G.D. MacLean. 1993. Immune responses of mice and human breast cancer patients following immunization with synthetic sialyl-Tn conjugated to KLH plus detox adjuvant. Ann. NY Acad. Sci. 690:276-291.
34. MacLean, G.D., M.A. Reddish, R.R. Koganty, T. Wong, S. Gandhi, M. Smolnski, J. Samuel, J.M. Nabholtz, and B.M. Longenecker. 1993. Immunisation of breast cancer patients using a synthetic sialyl-Tn glycoconjugate plus Detox adjuvant. Cancer Immunol. Immunother. 36:215-222.
35. O'Boyle K.P., R. Zamore, S. Adluri, A. Cohen, N. Kemeny, S. Welt, K. Lloyd, H.F. Oettgen, L.J. Old, and P.O. Livingston. 1992. Immunization of colorectal cancer patients with modified ovine submaxillary gland mucin and adjuvants induces igm and igg antibodies to sialylated Tn. Cancer Res. 52:5663-5667.
36. MacLean, G.D., M.A. Reddish, R.R. Koganty, and B.M. Longenecker. 1996. Antibodies against mucin-associated Sialyl-Tn epitopes correlate with survival of metastatic adenocarcinoma patients undergoing active specific immunotherapy with synthetic STn vaccine. J. Immunother. 19:59-68.
37. Rowley, M.J., M.E. Gershwin, and I.R. Mackay 1993. Molecular biology of autoantigens in primary biliary cirrhosis. In The Molecular Pathology of Autoimmunity. C.A. Bona, K. Simonovitch, A.N. Theofilopoulos, and M. Zanetti, editors. Harwood Academic Publishers, Reading, UK. 627-642.
38. Atkinson, M.A. and N.K. Maclaren. 1994. The pathogenesis of insulin dependent diabetes mellitus. N. Engl. J. Med. 331:1428-1436.
39. Mosmann, T.R., and R.L. Coffman. 1989. TH1 and TH2 cells: different patterns of lymphokine secretion lead to different functional properties. Annu. Rev. Immunol. 7:145-173.
40. Rughetti, A., V. Turchi, C.A. Ghetti, G. Scambia, P.B. Panici, G. Roncucci, S. Mancuso, L. Frati, and M. Nutti. 1993. Human B-cell immune response to the polymorphic epithelial mucin. Cancer Res. 53:2457-2459.
41. Von Mensdorff-Pouilly, S., M.M. Gourevitch, P. Kenemans, A.A. Verstraeten, S.V. Litvonov, G.J. van Kamp, S. Meijer, J. Vermorken, and J. Hilgers. 1996. Humoral immune response to polymorphic epithelial mucin (MUC-1) in patients with benign and malignant breast tumours. Eur. J. Cancer. 32:1325-1331.
42. Gourevitch, M.M., S. von Mensdorff-Pouilly, S.V. Litvonov, P. Kenemans, G.J. van Kamp, A.A. Verstraeten, and J. Hilgers. 1995. Polymorphic epithelial mucin (MUC-1)-containing circulating immune complexes in carcinoma patients. Brit. J. Canc. 72:934-938.
43. Petrarca, C., A. Rughetti, H. Rahimi, F. D'Agostini, V. Turchi, C. Apollonj Ghetti, G. Scambia, L. Frati, and M. Nutti. 1996. Human antibodies against the polymorphic epithelial mucin in ovarian cancer patients recognize a novel sequence in the tandem repeat region. Eur. J. Cancer. 32:2155-2163.
44. Burchell, J., J. Taylor-Papadimitriou, M. Boshell, S. Gendler, and T. Duhig. 1989. A short sequence, within the tandem repeat of a cancer-associated mucin, contains immunodominant epitopes. Int. J. Cancer. 44:691-696.
45. Apostolopoulos, V., J.S. Haurum, and I.F.C. McKenzie. 1997. MUC1 peptide epitopes associated with multiple H-2 Class I molecules. Eur. J. Immunol. In press.
46. Apostolopoulos, V., V. Karanikas, J.S Haurum, L.A. Sherman, and I.F.C. McKenzie. 1997. Induction of HLA-A2 restricted cytotoxic T lymphocytes to the MUC1 human breast cancer antigen. J. Immunol. In press.
47. Nakao, M., H. Yamana, Y. Imai, Y. Toh, U. Toh, A. Kimura, S. Yanoma, T. Kakegawa, and K. Itoh. 1995. HLA A2601-restricted CTLs recognise a peptide antigen expressed on squamous cell carcinoma. Cancer Res. 55:4248-4252.
48. Ressing, M.E., W.J. van Driel., E. Celis., A. Sette, R.M.P. Brandt, M. Hartman, J.D.H. Anholts, G.M.T. Schreuder, W. Bram Ter Harmsel, G. Jan Fleuren, B.J. Trimbos, W.M. Kast, and C.J.M. Melief. 1996. Occasional memory cytotoxic T cell responses of patients with human papilloma virus type 16-positive cervical lesions against a human leukocyte antigen-A*0201-restricted E7-encoded epitope. Cancer Res. 56:582-588.
49. Boon, T., and J.C. Cerrotini. 1995. The cell-mediated immune response to tumours. In Oxford Textbook of Oncology. Volume 1. M. Peckham, H. Pinedo, and U. Veronesi, editors. Oxford University Press, New York. 73-81.
50. Rammensee, H.-G., T. Friede, and S. Stevanovic. 1995. MHC ligands and peptide motifs: first listing. Immunogenetics. 41:178-228.
51. Redfield, R.R., D.L. Birx, N. Ketter, E. Tramont, V. Polonis, C. Davis, J.F. Brundage, G. Smith, S. Johnson, A. Fowler, et al. 1991. A phase I evaluation of the safety and immunogenicity of vaccination with recombinant gp160 in patients with early human immunodeficiency virus infection. N. Eng. J. Med. 324:1677-1684.
52. Marchand, M., P. Weynants, E. Rankin, F. Arienti, F. Belli, G. Parmiani, N. Cascinelli, A. Bourlond, R. Vanwijck, Y. Humblet, et al. 1995. Tumour regression responses in melanoma patients treated with a peptide encoded by gene MAGE-3. Int. J. Cancer. 63:883-885.
53. Goydos, J.S., E. Elder, T.L. Whiteside, O.J. Finn, and M.T. Lotze. 1996. A phase I trial of a synthetic mucin peptide vaccine. Induction of specific immune reactivity in patients with adenocarcinoma. J. Surg. Res. 63:298-304.
54. Topfer, F., T. Gordon, and J. McCluskey. 1995. Intra- and intermolecular spreading of autoimmunity involving the nuclear self-antigens La (SS-B) and Ro (SS-A). Proc. Natl. Acad. Sci. USA. 92:875.
55. Disis, M.L., E. Calenoff, G. McLaughlin, A.E. Murphy, W. Chen, B. Groner, M. Jeschke, N. Lydon, E. McGlynn, R.B. Livingston, et al. 1994. Existent T-cell and antibody immunity to HER-2/neu protein in patients with breast cancer. Cancer Res. 54:16-20.
56. Houbiers, J.G., H.W. Nijman, S.H. van der Burg, J.W. Drijfhout, P. Kenemans, C.J. van de Velde, A. Brand, F. Momburg, W.M. Kast, and C.J. Melief. 1993. In vitro induction of human cytotoxic T lymphocyte responses against peptides of mutant and wild-type p53. Eur. J. Immunol. 23:2072-2077.
57. Schwartz, R.H. 1993. T cell anergy. Sci. Am. 269:48-54.
58. Fairchild, P.J., and D.C. Wraith. 1996. Lowering the tone: mechanisms of immunodominance among epitopes with low affinity for MHC. Immunol. Today. 17:80-85.
59. Matzinger, P. 1994. Tolerance, danger, and the extended family. Annu. Rev. Immunol. 12:991-1045.